Spoken Alpha
ARROWHEAD PHARMACEUTICALS, INC.
Arrowhead Pharmaceuticals develops RNA interference-based medicines that silence disease-causing genes to treat intractable diseases across multiple therapeutic areas including cardiovascular, metabolic, neurological, and rare genetic disorders.
ARROWHEAD PHARMACEUTICALS, INC is a Healthcare company operating in Biotechnology with a $11.70B market cap.
ARWR missed consensus EPS by 0.0% in Q4 FY2026, reported Sep 29, 2026.
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Disclosures
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for ARWR.
$ curl https://api.spokenalpha.com/v1/companies/ARWRFAQ
Spoken Alpha indexes ARWR's earnings call transcripts at https://spokenalpha.com/companies/ARWR. Each call links to attributed speakers and parsed analyst Q&A.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) held its most recent earnings call on 2026-05-07, covering fiscal Q2 2026.
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 2026-09-29 | $-1.36 | $-1.35 | -1.0% | — | — | — | Finnhub |
| Q3 FY2026 | 2026-08-03 | $-1.36 | $-1.23 | -10.6% | $75.3M | — | — | EODHD |
| Q2 FY2026 | 2026-05-06 | $-0.93 | $-1.11 | +16.2% | $73.7M | — | — | EODHD |
| Q1 FY2026 | 2026-02-04 | $0.22 | $-0.37 | +100.0% | $264.0M | — | — | EODHD |
| Q4 FY2025 | 2025-11-24 | $-0.11 | $-0.31 | +64.5% | $256.5M | — | — | EODHD |
| Q3 FY2025 | 2025-08-06 | $-1.26 | $-0.94 | -34.0% | $27.8M | — | — | EODHD |
| Q2 FY2025 | 2025-05-11 | $2.75 | $-0.46 | +100.0% | $542.7M | — | — | EODHD |
| Q1 FY2025 | 2025-02-09 | $-1.39 | $-0.72 | -93.1% | $2.5M | — | — | EODHD |
| Q4 FY2024 | 2024-11-26 | $-1.37 | $-0.92 | -48.6% | $23.6M | — | — | EODHD |
| Q3 FY2024 | 2024-08-07 | $-1.38 | $-0.59 | -100.0% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-05-08 | $-1.02 | $-0.20 | -100.0% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-02-05 | $-1.24 | $-0.83 | -49.4% | $3.6M | — | — | EODHD |
| Q4 FY2023 | 2023-11-28 | $-1.02 | $-0.60 | -70.0% | $16.1M | — | — | EODHD |
| Q3 FY2023 | 2023-08-06 | $-0.96 | $-0.53 | -81.1% | $15.8M | — | — | EODHD |
| Q2 FY2023 | 2023-05-01 | $0.45 | $-0.59 | +100.0% | $146.3M | — | — | EODHD |
| Q1 FY2023 | 2023-02-05 | $-0.39 | $0.13 | -100.0% | $62.5M | — | — | EODHD |
| Q4 FY2022 | 2022-11-27 | $-0.81 | $-0.17 | -100.0% | $31.6M | — | — | EODHD |
| Q3 FY2022 | 2022-08-03 | $-0.68 | $-0.51 | -33.3% | $32.4M | — | — | EODHD |
| Q2 FY2022 | 2022-05-09 | $0.41 | $0.18 | +100.0% | $151.8M | — | — | EODHD |
| Q1 FY2022 | 2022-02-01 | $-0.60 | $-0.58 | -3.5% | $27.4M | — | — | EODHD |
Source: EODHD, Finnhub. ARWR reported actuals as published; sparse fields render as —.